Last updated on May 2018

Human Mesenchymal Stem Cells (LMSCs) on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty

Brief description of study

This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of LMCSs for improving vaccine immune response.

Detailed Study Description

A pilot phase will consist of a 3 subject safety run-in, followed by 20 subject randomized phase to evaluate influenza vaccine response at 1 week and 4 weeks post infusion of LMSCs. This will be followed by a double-blinded, randomized, placebo-controlled phase.

Clinical Study Identifier: NCT02982915

Contact Investigators or Research Sites near you

Start Over

Dushyantha T. Jayaweera, MD

University of Miami
Miami, FL United States
  Connect »

Antonio Blanco, MD

Vista Health Research
Miami, FL United States
  Connect »

Jeffrey Rosen, MD

Clinical Research of South Florida
Coral Gables, FL United States
  Connect »

Pedro P Ylisastigui, MD

Clinical Physiology Associates
Fort Myers, FL United States
  Connect »